Bayer's Leadership Prepares For First Innovative Drug Launch In China Ahead Of U.S.
This article was originally published in The Pink Sheet Daily
Executive Summary
Speedier action by Chinese regulators than by their U.S. counterparts could become common as Bayer Schering institutes its new policy of launching simultaneous clinical trials in the U.S., the EU, and China, exec says.